| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021577294 |
| P356 | DOI | 10.2165/00003088-198308050-00001 |
| P698 | PubMed publication ID | 6627809 |
| P2093 | author name string | D D Breimer | |
| P2860 | cites work | Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man | Q34449586 |
| Environmental factors affecting antipyrine metabolism in London factory and office workers | Q34517058 | ||
| Family study of antipyrine clearance | Q34746094 | ||
| Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins | Q35469675 | ||
| Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance | Q36105459 | ||
| 3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance | Q36645599 | ||
| Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol | Q39288636 | ||
| The antipyrine test in clinical pharmacology: Conceptions and misconceptions | Q39676489 | ||
| Genetic and environmental factors affecting drug disposition in man | Q39708309 | ||
| Individual Differences in the Disposition of Drugs Metabolised in the Body | Q39720658 | ||
| Assessment of Methods to Identify Sources of Interindividual Pharmacokinetic Variations | Q40108050 | ||
| Defective oxidation of drugs: pharmacokinetic and therapeutic implications | Q40329696 | ||
| Intraindividual variation in drug disposition | Q40723411 | ||
| Multiplicity of mammalian microsomal cytochromes P-45 | Q41203588 | ||
| Assay of Antipyrine and Its Primary Metabolites in Plasma, Saliva and Urine by High-Performance Liquid Chromatography and Some Preliminary Results in Man | Q41705893 | ||
| Factors affecting antipyrine metabolism in West African villagers | Q44188540 | ||
| Environmental effects on antipyrine half-life in man. | Q46532923 | ||
| Differential induction of antipyrine metabolism by rifampicin. | Q53701115 | ||
| Interindividual differences in drug oxidation: clinical importance. | Q53715264 | ||
| A case of deficiency of N-hydroxylation of amobarbital | Q67011355 | ||
| Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity | Q70264232 | ||
| Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time | Q70336540 | ||
| E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation | Q70823716 | ||
| Influence of the Genetically Controlled Deficiency in Debrisoquine Hydroxylation on Antipyrine Metabolite Formation | Q70887429 | ||
| Antipyrine metabolism in the rat by three hepatic monooxygenases | Q71274183 | ||
| Ethnic differences in drug metabolism | Q71452908 | ||
| Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig | Q72521276 | ||
| Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies | Q72555717 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 371-377 | |
| P577 | publication date | 1983-09-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Interindividual variations in drug disposition. Clinical implications and methods of investigation | |
| P478 | volume | 8 |
| Q35640730 | "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? |
| Q34621796 | 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine |
| Q90903705 | ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches |
| Q68437539 | Antipyrine Pharmacokinetics in Women Receiving Conjugated Estrogens |
| Q34447041 | Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia |
| Q42040905 | Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis |
| Q72747532 | Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment |
| Q43949330 | Antipyrine metabolite formation and excretion in patients with chronic renal failure |
| Q71497746 | Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs |
| Q40191967 | Cigarette smoking pharmacokinetics and its relationship to smoking behaviour |
| Q32117273 | Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites |
| Q69720901 | Comparison of trimethadione and antipyrine as indicators of oxidative drug metabolizing capacity in man |
| Q86836795 | Correlation between in vivo antipyrine metabolite formation and theophylline metabolism in rats |
| Q38716927 | Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies |
| Q51777849 | Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. |
| Q78019948 | Effect of tacrine hydrochloride on hepatic drug metabolism |
| Q55264312 | Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs. |
| Q68358322 | Elimination of cotinine from body fluids |
| Q93534039 | Elimination of cotinine from body fluids: disposition in smokers and nonsmokers |
| Q42867703 | Evaluation of CYP2C9 Activity in Rats: Use of Tolbutamide Alone and in Combined with Bupropion. |
| Q40839213 | Evaluation of a novel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-4-(aminomethyl)-coumarin |
| Q51832268 | Evaluation of infusion regimens for thiopentone as a primary anaesthetic agent. |
| Q68048932 | Gas chromatographic determination of sparteine and 2- and 5-dehydrosparteine in plasma and urine |
| Q34682168 | Genetically determined variability in acetylation and oxidation. Therapeutic implications |
| Q67927805 | Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation |
| Q44673368 | Incidence of a subclinical fascioliasis on antipyrine clearance and metabolite excretion in sheep |
| Q40791116 | Individual variation in first-pass metabolism |
| Q41836161 | Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative |
| Q70733898 | Influence of alaproclate on antipyrine metabolite formation in man |
| Q93646835 | Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump |
| Q41170834 | Influence of nutrition on liver oxidative metabolism |
| Q34621602 | Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis |
| Q61794905 | Inhibition and induction of metronidazole and antipyrine metabolism |
| Q41914937 | Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro |
| Q40845851 | Inhibitory effect of nicotine and its metabolites on tolbutamide hydroxylation in rat liver microsomes |
| Q34358130 | Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. |
| Q34448167 | Obesity effects on nitrazepam disposition |
| Q42015699 | Partial metabolic clearances as determinants of the oral bioavailability of propranolol |
| Q41919910 | Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug |
| Q69812035 | Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver |
| Q37713715 | Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites |
| Q34418061 | Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach |
| Q93560199 | Research in the Division of Pharmacology |
| Q64130397 | Risk Assessment: Extrapolation to Individual Risk |
| Q70028173 | Salivary antipyrine half-life during injectable progestagen contraception |
| Q68411894 | Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide |
| Q34417536 | Simplified approaches to the determination of antipyrine pharmacokinetic parameters |
| Q30963437 | Solid phase extraction and simultaneous high performance liquid chromatographic determination of antipyrine and its major metabolites in urine |
| Q41323109 | The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk |
| Q73567801 | The effect of velnacrine on the mixed function oxidase system |
| Q42284969 | The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates |
| Q28361778 | The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites |
| Q70490332 | The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women |
| Q41647373 | Trimethadione as a probe drug to estimate hepatic oxidizing capacity in humans. |
| Q69948291 | Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man |
| Q73846452 | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes |
| Q41816741 | Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses |
Search more.